A method for synthesizing a thioimidazoline analog
By directly reacting p-aminophenol with methyl 2-bromoisobutyrate, the phenolic hydroxyl group is introduced into the propenyl group and directly converted into the molecular skeleton. The cyclization reaction does not require strong acid reagents, which solves the problems of high cost and environmental unfriendliness in the synthesis of thioimidazoline analogs revelulamine in the prior art, and realizes an efficient and economical synthesis method.
Patent Information
- Application Number
- CN202611408912.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-11
- Publication Date
- 2026-11-17
AI Technical Summary
Existing methods for synthesizing the thioimidazoline analog revelulamide suffer from problems such as high production costs, environmental unfriendliness, and operational difficulties. In particular, the use of expensive and strongly acidic reagents leads to high costs and increased waste.
Intermediate 2 was obtained by directly reacting p-aminophenol with methyl 2-bromoisobutyrate. The phenolic hydroxyl group was introduced into the propenyl group as a protecting group and directly converted into the molecular skeleton. The cyclization reaction did not use strong acid reagents and introduced a chiral center through an asymmetric reaction, thus avoiding chiral resolution.
It significantly reduces production costs, improves the atom economy and environmental friendliness of the process, simplifies operating procedures, and reduces reagent use and waste generation.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to a method for synthesizing thioimidazoline analogs, belonging to the field of pharmaceutical intermediate synthesis technology. Background Technology
[0002] Revelulide, a thioimidazoline analogue (trade name: Aieren), was independently developed by Hengrui Medicine and is the first original novel androgen receptor (AR) inhibitor approved for marketing in my country. It is specifically designed for patients with metastatic hormone-sensitive prostate cancer (mHSPC) with a high tumor burden, filling the gap in innovative drugs in this field in China.
[0003] The drug incorporates dihydroxyl groups in its molecular structure design to enhance hydrophilicity, resulting in significant clinical benefits: reduced central nervous system toxicity, with significantly lower blood-brain barrier permeability compared to similar marketed products, thereby effectively reducing adverse reactions related to the central nervous system such as dizziness, weakness, and fatigue; high activity and optimized metabolism, maintaining high activity against AR while possessing more optimized pharmacokinetic characteristics, ensuring stable release and absorption of the drug in vivo.
[0004] Hengrui's patent US2015225381A1 uses p-aminophenol as a raw material, and prepares an intermediate through substitution, addition, and ring closure. This intermediate is then substituted with an epoxy halide, followed by ring opening and chiral resolution to obtain revivalidine. The reaction equation is as follows:
[0005] This method first prepares a racemic product, which is then chirally resolved to obtain revivalidine, resulting in a material loss of at least 50%. The first step uses the expensive and hazardous reagent TMSCN, increasing production costs. The second step, ring closure, uses a large amount of strongly acidic concentrated hydrochloric acid to hydrolyze the imine, increasing waste and making it environmentally unfriendly.
[0006] Patent CN113929628A uses the intermediate from patent US2015225381A1, introducing (R)-(-)-glycerol acetal into the chiral fragment, followed by deprotection to obtain revivalidine. The reaction equation is as follows:
[0007] The intermediate synthesis of this route still uses regulated drugs and expensive addition reagents, while the chiral fragment material (R)-(-)-glycerol is expensive, increasing production costs.
[0008] The literature ACS Medicinal Chemistry Letters, 2020, vol. 11, #8, pp. 1539-1547 mentions the following method for synthesizing the intermediate:
[0009] This route uses benzyl-protected p-hydroxyaniline for substitution, cyclization, and deprotection to obtain intermediates, which reduces atom economy. Furthermore, the deprotection process uses expensive, strongly acidic boron trifluoride diethyl ether reagent, and the reaction temperature is extremely low, which greatly increases the difficulty of operation and production costs.
[0010] Patent CN116199633A uses (S)-3-chloro-1,2-propanediol for protection, substitution, and coupling, followed by deprotection to obtain revivalidine. The reaction equation is as follows:
[0011] Although the initial raw material (S)-3-chloro-1,2-propanediol used in this route helps reduce the cost of chiral elements, the TBS and p-bromophenol protecting groups used are expensive and used in large quantities. The coupling reaction introduces metal ions, which brings difficulties and safety risks to subsequent operations, all of which significantly increase the production cost of the product. Summary of the Invention
[0012] To overcome the aforementioned technical deficiencies, this invention provides an economical and efficient method for synthesizing the thioimidazoline analog revertamine. The method's technical features include: A) Optimized conditions promote the direct reaction of p-aminophenol with methyl 2-bromoisobutyrate to obtain intermediate 2, resulting in economic efficiency. B) The phenolic hydroxyl group in intermediate 2 is introduced into the propenyl group, serving both as a protecting group and directly converting into the molecular skeleton, avoiding conventional protecting group conversion and improving the atom economy of the process. C) During the ring-closure of intermediate 2, the use of strong acidic reagents such as concentrated hydrochloric acid is unnecessary, significantly reducing operating costs and improving environmental friendliness. D) The direct asymmetric reaction of the olefin bond introduces a chiral center, substantially reducing the product production cost.
[0013] This invention first provides thioimidazoline compound 4, the structure of which is as follows:
[0014] This invention provides the application of the above-mentioned thioimidazoline compound 4 in revivalidine and its analogues (i.e., a new method for synthesizing the thioimidazoline analogue revivalidine).
[0015] The novel method for synthesizing the thioimidazoline analog revertamide according to the present invention includes the following steps:
[0016] Step 1, substitution reaction: p-aminophenol reacts with methyl 2-bromoisobutyrate in an organic solvent in the presence of a base to give compound 2; The second step, substitution reaction: Compound 2 reacts with 3-bromopropene in an organic solvent in the presence of a base to give compound 3; The third step, cyclization reaction: Compound 3 reacts with 4-isothiocyano-2-(trifluoromethyl)benzonitrile in an organic solvent to give compound 4; Step 4, dihydroxylation: Compound 4 is reacted in organic solvent A in the presence of an oxidant, an additive and a chiral ligand, or epoxidized in organic solvent B in the presence of tetraisopropyl titanate, a chiral inducer and tert-butyl hydroperoxide, and then ring-opened to obtain the thioimidazoline analog revelutamide 5.
[0017] Furthermore, in the above technical solution, the molar ratio of p-aminophenol, methyl 2-bromoisobutyrate, and alkali in the first step is 1:1.0-1.5:2.0-4.0.
[0018] Furthermore, in the above technical solution, the alkali mentioned in the first step is selected from potassium carbonate, sodium carbonate, potassium hydroxide, or sodium bicarbonate; the organic solvent is selected from DMF, DMSO, or acetonitrile; and the reaction temperature is 80-100 ℃.
[0019] Furthermore, in the above technical solution, the alkali mentioned in the second step is selected from triethylamine, diisopropylethylamine, potassium hydroxide, or potassium carbonate; the organic solvent is selected from acetone, DMF, acetonitrile, or DMSO.
[0020] Furthermore, in the above technical solution, the organic solvent in the third step is selected from DMF / isopropyl acetate, DMSO / isopropyl acetate, DMF, NMP or DMSO; the reaction temperature is 50-80 ℃.
[0021] Furthermore, in the above technical solution, the organic solvent A in the fourth step is selected from tert-butanol, tert-butanol / water, or n-butanol / water; the reaction temperature is 20-40 ℃.
[0022] Furthermore, in the above technical solution, the chiral ligand in the fourth step is selected from hydrogenated quinine 1,4-(2,3-diazanaphthalene) diether or hydrogenated quinine-2,5-diphenyl-4,6-pyrimidine dimethyl ether; the selected oxidant is selected from potassium osmium tetroxide or osmium tetroxide; and the additive is selected from sodium bicarbonate or methanesulfonamide.
[0023] Furthermore, in the above technical solution, the chiral inducing agent in the fourth step is selected from optically pure diethyl tartrate, diisopropyl tartrate, D-1,2:4,5-di-o-isopropylene-BD-red-2,3-hexyl or Jacobson catalyst; the organic solvent B is selected from tetrahydrofuran / water or acetonitrile / water.
[0024] Compared with the prior art, the present invention has achieved the following technical advancements: 1. This invention uses p-aminophenol and methyl 2-bromoisobutyrate as raw materials to directly and economically obtain intermediate 2 without the need for phenolic hydroxyl protection, thus reducing the steps of protecting group removal. 2. The phenolic hydroxyl group is protected by a propenyl group to form a novel key intermediate 4, which combines the functions of the protecting group and the molecular skeleton, reflecting the atom economy of the process; the cyclization reaction does not require the use of a large amount of strong acid reagents.
[0025] 3. By using asymmetric bihydroxylation or asymmetric epoxidation followed by ring opening, chiral products can be obtained directly without the need for separation, greatly improving economic efficiency. Attached Figure Description
[0026] Figure 1 The HNMR spectrum of revelutidine in Example 4 of this invention; Figure 2 This is the chiral purity spectrum of revelutidine in Example 4 of the present invention; Figure 3 This is the liquid phase purity spectrum of retinoic acid in Example 4 of the present invention; Figure 4 The HNMR spectrum of key intermediate 4 in Embodiment 3 of the present invention; Figure 5 This is the LC-MS spectrum of the key intermediate 4 in Embodiment 3 of the present invention. Detailed Implementation Example 1
[0027] Under nitrogen protection, p-aminophenol (1.1 g, 0.01 mol), potassium carbonate (2.8 g, 0.02 mmol), and methyl 2-bromoisobutyrate (1.8 g, 0.01 mol) were dissolved in 5 mL of acetonitrile, and the reaction was stirred at 70 °C for 6 hours. After the reaction was complete as monitored by TLC, the reaction mixture was poured into 80 mL of ice water, extracted three times with 20 mL of ethyl acetate, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain crude product 2 (2.2 g, 100% yield). This crude product was used directly without further purification.
[0028] Example 2
[0029] Intermediate 2 (2.7 g, 0.013 mol) and 3-bromopropene (2.3 g, 0.019 mol) were added to acetone (50 mL), followed by potassium carbonate (3.6 g, 0.026 mol). The reaction was heated to 50 °C and stirred for 16 hours. The reaction was monitored by TLC until complete, then dissolved under reduced pressure and purified by column chromatography to give 3.1 g of intermediate 3, with a yield of 95%.
[0030] Example 3
[0031] Intermediate 3 (1 g, 4 mmol) and 4-isothiocyano-2-(trifluoromethyl)benzonitrile (1.32 g, 5.8 mmol) were added to DMSO (5 mL) and stirred at room temperature for 16 hours. The reaction was stopped by TLC. The reaction solution was added to 10 mL of water, extracted three times with dichloromethane, and the organic phases were combined and the crude product was concentrated and purified to obtain 1.5 g of intermediate 4, with a yield of 85%.
[0032] Example 4
[0033] Hydrogenated quinine 1,4-(2,3-diazanaphthalene) diether (86 mg, 0.11 mmol), potassium ferricyanide (2.2 g, 6.6 mmol), potassium osmium tetroxide dihydrate (684 mg, 2.2 mmol), potassium carbonate (1.52 g, 11 mmol), and methanesulfonamide (0.02 g, 0.22 mmol) were added to tert-butanol / water (10 mL / 10 mL). Then, intermediate 4 (1 g, 2.2 mmol) was added in portions under ice bath conditions, and the mixture was heated to room temperature and stirred for 16 hours. The reaction was stopped by TLC. The reaction solution was added to 20 mL of water, extracted with ethyl acetate, and the organic phases were combined and evaporated to dryness to obtain 1.1 g of crude product. Crystallization and purification yielded 0.7 g of revivalidine (70% yield).
[0034] Example 5
[0035] Under nitrogen protection, p-aminophenol (11 g, 0.01 mol), sodium carbonate (21 g, 0.02 mmol), and methyl 2-bromoisobutyrate (18 g, 0.01 mol) were dissolved in 50 mL of acetonitrile. The reaction was stirred at 70 °C for 6 hours. After TLC monitoring showed the reaction was complete and somewhat turbid, the reaction solution was poured into 200 mL of ice water and extracted with 100 mL of ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain intermediate 2 (12 g, 57% yield).
[0036] Example 6
[0037] Intermediate 2 (5 g, 0.024 mol) and 3-bromopropene (4.4 g, 0.036 mol) were added to an acetonitrile (50 mL) solution, followed by potassium carbonate (6.6 g, 0.048 mol). The reaction was heated to 50 °C and stirred for 16 hours. The reaction was monitored by TLC until complete, and then dissolved under reduced pressure. The solution was purified by column chromatography to give 4.1 g of intermediate 3, with a yield of 69%.
[0038] Example 7
[0039] Intermediate 3 (2 g, 8 mmol) and 4-isothiocyano-2-(trifluoromethyl)benzonitrile (2.64 g, 11.6 mmol) were added to DMSO / isopropyl acetate (10 / 10 mL) and stirred at room temperature for 16 hours. After the reaction was complete as determined by TLC, the reaction solution was added to 100 mL of water, extracted three times with dichloromethane, and the combined organic phases were concentrated. The crude product was purified by column chromatography to obtain 2.5 g of intermediate 4, with a yield of 70%.
[0040] Example 8
[0041] Hydrogenated quinine 1,4-(2,3-diazanaphthalene) diether (172 mg, 0.22 mmol), potassium ferricyanide (4.3 g, 13.2 mmol), potassium osmium tetroxide dihydrate (1.4 g, 4.4 mmol), and potassium carbonate (3 g, 22 mmol) were added to tert-butanol / water (30 mL / 30 mL). Then, intermediate 4 (2 g, 4.4 mmol) was added in portions under ice bath conditions, and the mixture was heated to room temperature and stirred for 16 hours. The reaction was stopped by TLC. The reaction solution was added to 20 mL of water, extracted with ethyl acetate, and the organic phases were combined and evaporated to dryness to obtain 2.1 g of crude product. After crystallization and purification, 1.2 g of revertamine was obtained, with a yield of 55%.
[0042] Example 9
[0043] Under nitrogen protection, diethyl D-tartrate (460 mg, 2.2 mmol) and tetraisopropyl titanate (620 mg, 2.2 mmol) were added to anhydrous dichloromethane (100 mL). A 5M solution of tert-butylperoxide (decane) (4.8 mL, 24 mmol) was added dropwise at -20 °C. After stirring for 30 minutes, intermediate 4 (10 g, 22 mmol) / dichloromethane (50 mL) solution was added dropwise to the mixture. The mixture was stirred at this temperature for 6 hours after the addition was complete. The reaction was confirmed by TLC. 200 mL of saturated potassium sodium tartrate aqueous solution was added to the reaction mixture, followed by dichloromethane extraction. The organic phases were combined and evaporated to dryness to obtain 11 g of crude product. Column chromatography yielded 8 g of intermediate 6, with a yield of 80%.
[0044] Example 10
[0045] Intermediate 6 (2.9 g, 6.3 mmol) was added to tetrahydrofuran / water (15 / 15 mL). Then, concentrated sulfuric acid (2 mL) was added, and the mixture was stirred at room temperature for 4 hours. The reaction was stopped by TLC. The reaction solution was extracted with ethyl acetate, evaporated to dryness, and purified by crystallization to give 2.1 g of revertamine, with a yield of 70%.
[0046] Comparative Example 1
[0047]
[0048] p-Aminophenol (4.0 g, 0.037 mol) was dissolved in acetone / dichloromethane (24 / 48 mL), and trimethylsilyl cyanide (7.4 mL, 0.055 mmol) and trimethylsilyl trifluoromethanesulfonate (0.3 mL, 1.84 mmol) were added. The reaction was stirred at room temperature for 12 hours. The reaction was monitored by TLC until completion, and the crude product was obtained by rotary evaporation. Intermediate B of the crude product was purified by column chromatography to obtain intermediate B (2.1 g, yield 31%).
[0049] Comparative Example 2
[0050] Intermediate B (1.5 g, 8.51 mmol) and 4-isothiocyanate-2-(trifluoromethyl)benzonitrile (2.90 g, 12.75 mmol) were dissolved in 5 mL of N,N-dimethylacetamide. The reaction solution was heated to 60 °C and reacted for 1.5 hours. The reaction was then stopped by TLC. 20 mL of methanol and 20 mL of concentrated hydrochloric acid were added to the reaction solution, and the mixture was stirred at room temperature for 16 hours. TLC showed that a large amount of intermediates remained unconverted. The reaction solution was then heated to 40 °C and reacted for 6 hours. The reaction was then stopped by TLC. The reaction solution was added to water and extracted with ethyl acetate (50 mL x 3). The organic phases were combined, washed with saturated sodium chloride solution (20 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography to obtain intermediate C (3.0 g, 87% yield).
[0051] Comparative Example 3
[0052] Intermediate C (4.5 g, 0.01 mol) and potassium carbonate (3.0 g, 0.02 mmol) were added to acetonitrile (50 mL), followed by dropwise addition of (S)-epimylochloropropane (1.6 g, 0.015 mol). The solution was then heated to 80 °C and stirred for 16 hours. The reaction was stopped by TLC. The reaction solution was cooled, the solid was removed by filtration, and the crude product was concentrated and purified by column chromatography to obtain 2.2 g of intermediate 6, with a yield of 41%.
[0053] Comparative Example 4 Intermediate 6 (2.0 g, 4.3 mmol) was added to tetrahydrofuran / water (10 / 10 mL). Then, concentrated sulfuric acid (1.4 mL) was added, and the mixture was stirred at room temperature for 4 hours. The reaction was stopped by TLC. The reaction solution was extracted with ethyl acetate, evaporated to dryness to obtain the crude product, and purified by crystallization to give 1.4 g of revertamine, with a yield of 70%.
[0054] The above are merely preferred embodiments of the present invention. It should be noted that the above preferred embodiments should not be considered as limitations on the present invention, and the scope of protection of the present invention should be determined by the scope defined in the claims. For those skilled in the art, several improvements and modifications can be made without departing from the spirit and scope of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. A method for synthesizing the thioimidazoline analog revertamide, characterized in that, Includes the following steps: ; Step 1, substitution reaction: p-aminophenol reacts with methyl 2-bromoisobutyrate in an organic solvent in the presence of a base to give compound 2; The second step, substitution reaction: Compound 2 reacts with 3-bromopropene in an organic solvent in the presence of a base to give compound 3; The third step, cyclization reaction: Compound 3 reacts with 4-isothiocyano-2-(trifluoromethyl)benzonitrile in an organic solvent to give compound 4; Step 4, dihydroxylation: Compound 4 is reacted in organic solvent A in the presence of an oxidant, an additive and a chiral ligand, or epoxidized in organic solvent B in the presence of tetraisopropyl titanate, a chiral inducer and tert-butyl hydroperoxide, and then ring-opened to obtain the thioimidazoline analog revelutamide 5.
2. The method for synthesizing the thioimidazoline analog revertamine according to claim 1, characterized in that: In the first step, the molar ratio of p-aminophenol, methyl 2-bromoisobutyrate, and alkali is 1:1.0-1.5:2.0-4.
0.
3. The method for synthesizing the thioimidazoline analog revertamide according to claim 1, characterized in that: In the first step, the alkali is selected from potassium carbonate, sodium carbonate, potassium hydroxide, or sodium bicarbonate; the organic solvent is selected from DMF, DMSO, or acetonitrile; and the reaction temperature is 80-100 ℃.
4. The method for synthesizing the thioimidazoline analog revertamide according to claim 1, characterized in that: In the second step, the alkali is selected from triethylamine, diisopropylethylamine, potassium hydroxide, or potassium carbonate; the organic solvent is selected from acetone, DMF, acetonitrile, or DMSO.
5. The method for synthesizing the thioimidazoline analog revertamide according to claim 1, characterized in that: The third step involves selecting the organic solvent from DMF / isopropyl acetate, DMSO / isopropyl acetate, DMF, NMP, or DMSO; and the reaction temperature is 50-80℃.
6. The method for synthesizing the thioimidazoline analog revertamide according to claim 1, characterized in that: In the fourth step, the organic solvent A is selected from tert-butanol, tert-butanol / water, or n-butanol / water; the reaction temperature is 20-40 ℃.
7. The method for synthesizing the thioimidazoline analog revertamide according to claim 1, characterized in that: Fourth step, the chiral ligand is selected from hydrogenated quinine 1,4-(2,3-diazanaphthalene) diether or hydrogenated quinine-2,5-diphenyl-4,6-pyrimidine dimethyl ether; the selected oxidant is selected from potassium osmium tetroxide or osmium tetroxide; the additive is selected from sodium bicarbonate or methanesulfonamide.
8. The method for synthesizing the thioimidazoline analog revertamine according to claim 1, characterized in that: In the fourth step, the chiral inducing agent is selected from optically pure diethyl tartrate, diisopropyl tartrate, D-1,2:4,5-di-o-isopropylene-BD-red-2,3-hexyl or Jacobson catalyst; the organic solvent B is selected from tetrahydrofuran / water or acetonitrile / water.
9. Thioimidazoline compound 4, its structure is as follows: 。 10. The use of the thioimidazoline compound 4 as described in claim 9 in revelutamide and its analogues.
Citation Information
Patent Citations
Preparation method of imidazoline derivative
CN113929628A
Method for preparing revialutamide
CN116199633A
Imidazoline derivatives, preparation methods thereof, and their applications in medicine
US20150225381A1
